phrykt

Biohaven Ltd. (BHVN): who owns it and who trades it

As of Nov 16, 2026, BHVN insiders reported 1 purchase worth $145K in the last 12 months. The largest buyer was George C. Clark (Vice president), with $145K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Biohaven

From the latest filings

Overall: more buying than selling. Insiders mostly bought. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BHVN

294 funds and institutions reported BHVN shares worth $2.1B at the end of Q2 2026, about 94% of the company. The largest holder is BlackRock, Inc. with 8.8%.

Funds and institutions (13F) 94%Everyone else 6%

10 largest owners, by share of the company

BlackRock, Inc.8.8%
Montanova Capital, LLC6.8%
Stifel Financial Corp6.6%
Jupiter Topco LLC5.7%
Woodline Partners LP5.1%
State Street Corp4.6%
Infinitum Asset Management, LLC4.2%
D. E. Shaw & Co., Inc.2.8%
AQR Capital Management LLC2.8%
Geode Capital Management, LLC2.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.13.21M8.77%$197M+18%
Montanova Capital, LLC10.29M6.83%$153MNo change
Stifel Financial Corp9.94M6.60%$148MNo change
Jupiter Topco LLC8.58M5.70%$128M–
Woodline Partners LP7.66M5.09%$114M+2450%
State Street Corp6.95M4.61%$103M+5%
Infinitum Asset Management, LLC6.25M4.15%$93MNo change
D. E. Shaw & Co., Inc.4.19M2.78%$62.4M+47%
AQR Capital Management LLC4.15M2.76%$61.8M+110%
Geode Capital Management, LLC3.32M2.21%$49.5M+20%
FMR LLC (Fidelity)2.96M1.97%$44.1M+26%
Royalty Pharma Sub-Manager, LLC2.94M1.95%$43.7MNo change
Cormorant Asset Management, LP2.61M1.73%$38.8M+48%
Goldman Sachs Group Inc2.58M1.72%$38.4M+3%
UBS Group AG2.52M1.67%$37.5M+77%
Vanguard Portfolio Management LLC2.49M1.65%$37M+9%
Balyasny Asset Management L.P.1.88M1.25%$28M-23%
TCG Crossover Management, LLC1.78M1.18%$26.5M-62%
Nuveen, LLC1.74M1.16%$26M+134%
Rubric Capital Management LP1.72M1.14%$25.6M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, BHVN insiders reported $145K of open-market purchases and $0 of sales.

Purchases, 12 months
$145K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Nov 17, 2025
Filed Nov 18, 2025

Purchases and sales by month

$1$1DecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 17, 2025George C. ClarkVice presidentPurchase17,000$8.52$145KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
George C. ClarkVP, Chief Accounting Officer$145K–Nov 17, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BHVN short interest

Moderate short interest. 9.9% of BHVN shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 38%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 15.01M BHVN shares were sold short, 9.9% of the shares outstanding, down 16.1% from the report before. At the average daily volume of 5.11M shares, buying them all back would take about 2.9 trading days (days to cover).

Shares short, % of all shares

9.94%May 15Oct 3018.0%

Days to cover

2.9May 15Oct 3013.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202615.01M9.94%-16%5.11M2.9
Oct 15, 202617.90M11.85%-6%1.95M9.2
Sep 30, 202619.05M12.61%-7%2.96M6.4
Sep 15, 202620.45M13.54%+8%3.14M6.5
Aug 31, 202619.00M12.58%+7%3.97M4.8
Aug 14, 202617.82M11.80%-2%1.72M10.3
Jul 31, 202618.19M12.08%-6%1.96M9.3
Jul 15, 202619.35M12.85%-5%2.56M7.5
Jun 30, 202620.47M13.60%-20%4.86M4.2
Jun 15, 202625.50M16.94%+1%3.17M8.1
May 29, 202625.25M16.77%+5%2.94M8.6
May 15, 202624.10M16.00%-3%2.02M11.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Biohaven company events

Biohaven filed 15 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 29, 2026.

  1. Oct 29, 2026ResultsReleased financial results. Filing
  2. Oct 22, 2026AnnouncementShared information with investors. Filing
  3. Oct 15, 2026AgreementBiohaven Ltd., together with its wholly owned subsidiaries, entered into a Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd. Filing
  4. Sep 10, 2026AnnouncementBiohaven Ltd. is providing updates to the BHV-7000 program. Filing
  5. Aug 26, 2026AgreementBiohaven Bioscience Ireland Limited, a wholly owned subsidiary of Biohaven Ltd., entered into a License Agreement with SK Biopharmaceuticals Co., Ltd. Filing
  6. Aug 10, 2026ResultsReleased financial results. Filing
  7. Aug 7, 2026LeadershipThe Board of Directors of Biohaven Ltd. appointed John Yetimoglu as a director, effective August 6, 2026. Filing
  8. Jul 9, 2026LeadershipBiohaven Ltd. and Bruce Car, Ph.D., mutually agreed that, effective July 13, 2026, Dr. Car will retire as Chief Scientific Officer of the Company and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer. Filing
  9. May 27, 2026AnnouncementShared information with investors. Filing
  10. May 5, 2026AnnouncementBiohaven Ltd. entered into Amendment No. 2 to the Equity Distribution Agreement, dated October 2, 2023, as previously amended by Amendment No. 1, dated August 16, 2024 (“Amendment No. 1” and, together with the Original Equity Distribution Agreement and Amendment No. 2, the “Equity Distribution… Filing
  11. May 4, 2026ResultsReleased financial results. Filing
  12. May 4, 2026VoteReported shareholder vote results. Filing
  13. Mar 2, 2026ResultsReleased financial results. Filing
  14. Jan 12, 2026AnnouncementShared information with investors. Filing
  15. Jan 7, 2026AnnouncementBiohaven Ltd. agreed to issue and sell 12,500,000 common shares to Janus Henderson Investors at a purchase price of $10.00 per share. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Biohaven financials

Famous investors that hold BHVN

4 of the 50 well-known investors we track reported holding BHVN in their latest 13F filing. The largest position is Jim Simons's, worth $6.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026464,852$6.2M0.0%+208%
Ray Dalio · Bridgewater AssociatesQ3 2026100,249$1.3M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202663,606$849K0.0%-31%
Israel Englander · Millennium ManagementQ3 202636,728$490K0.0%-91%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BHVN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A1.4%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A1.4%

Questions about Biohaven Ltd. (BHVN) stock

Who owns the most BHVN stock?

The largest reported owner of Biohaven Ltd. (BHVN) is BlackRock, Inc., with 8.8% of the company. In total, 294 funds and institutions reported holding BHVN at the end of Q2 2026, together about 94% of the shares. See the largest owners.

Are BHVN insiders buying or selling?

In the last 12 months, BHVN insiders reported 1 open-market purchase worth $145K and no sales. The latest trade was on Nov 17, 2025. See every trade.

What is the short interest in BHVN?

As of Oct 30, 2026, 15.01M BHVN shares were sold short, 9.9% of the shares outstanding, down 16.1% from the report before. At the average daily volume of 5.11M shares, buying them all back would take about 2.9 trading days (days to cover). See the history.

Which famous investors hold BHVN?

4 of the 50 well-known investors we track reported BHVN in their latest 13F filing, including Jim Simons, Ray Dalio, Paul Tudor Jones. The largest position is worth $6.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.